3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Sarcoma
1
Lymphoid
1
CNS
1
Conditions
Skin Neoplasms
1
Multiple Sclerosis, Relapsing-Remitting
1
Multiple Sclerosis
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Carcinoma, Basal Cell
1
Interventions
Ipilimumab
123
pembrolizumab
101
Nivolumab
100
aldesleukin
89
Cyclophosphamide
85
fludarabine phosphate
64
Interleukin-2
58
Dacarbazine
57
3-ingenyl angelate
42
Vemurafenib
39
Temozolomide
39
Imiquimod
39
trametinib
37
sargramostim
37
Peripheral Blood Stem Cell Transplantation
36
incomplete Freund's adjuvant
35
dabrafenib
32
fludarabine
31
Radiotherapy
31
Aminolevulinic Acid
30
Bevacizumab
29
Carboplatin
28
Whole-Body Irradiation
25
Photochemotherapy
25
Paclitaxel
25
Filgrastim
25
Biopsy
25
Interferon-alpha
24
Cisplatin
23
Sorafenib
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Dimethyl Fumarate
×
Dermatologic
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled
NCT02546440
2023-03-31
DMF-CTCL
Universitätsmedizin Mannheim
Phase 2
Completed
25 enrolled